when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Big Pharma · news · pharmadog

← back to Big Pharma

News · Big Pharma

94 stories

28dRoche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onbiospace

28dGSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugbiospace

29dMake or break: Commercial hires critical for successbiospace

Jul 22, 26From Big Pharma to specialty: why moving closer to the patient changes everythingbiospace

Jul 22, 26AI data becomes sticking point in biopharma dealmakingbiospace

Jul 21, 26‘We’re moving quickly’: Startup bags rare disease drug as Thiel-backed CEO eyes $50M fundraisefiercebiotech

Jul 21, 26Biotech industry leaders file brief backing FDA against ‘malicious’ mifepristone challengefiercebiotech

Jul 21, 26Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsbiospace

Jul 21, 26‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealfiercebiotech

Jul 20, 26Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsbiospace

Jul 20, 26BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’fiercebiotech

Jul 18, 26‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsfiercebiotech

Jul 17, 26Compounders maintain a firm grip on the GLP-1 marketbiopharma dive

Jul 17, 26How well are AI-discovered drugs faring in the clinic?biopharma dive

Jul 17, 26BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsfiercebiotech

Jul 16, 26Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsbiopharma dive

Jul 16, 26Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckleyendpoints

Jul 6, 26Gene editing developer Scribe plots an IPObiopharma dive

Jul 6, 26Cancer, immune drugmakers dominate VC funding so far in 2026biopharma dive

Jul 1, 26Abivax shares surge as worries subside over immune drug’s cancer riskbiopharma dive

May 29, 26Can a chaotic FDA still deliver on faster drug development?biopharma dive

May 15, 26India’s pharma industry is going global. But can it catch up to China?biopharma dive

May 15, 26M&A isn’t just for big pharma. Mid-size companies are stepping up deal huntsendpoints

May 12, 26A year after Vertex’s big launch, pain drug research faces a pivotal momentbiopharma dive

May 12, 26STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugsstat

May 11, 26Biotech layoffs are easing, but is the worst over?biopharma dive

May 5, 26Cytospire hauls in $83M for a new type of T cell engagerbiopharma dive

May 1, 26Save the date: Premium subscriber-exclusive Post-Hoc Liveendpoints

May 1, 26Opinion: The psychedelic revolution is leaving behind people of colorstat

Apr 28, 26Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.biopharma dive

← prevpage 3 of 4next →